AAV is an acronym for Adeno-associated virus. They are the leading platform for gene delivery for the treatment of a variety of human diseases. The first AAV-based gene therapy drug, Glybera, was approved by the European Medicines Agency in 2012. This article has much more information.
Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.
Due to data protection policies, USA residents can not access our data.
Your content has been curated